drugset / Trial / NCT02428764
Neoadjuvant Nimotuzumab Plus Gemcitabine and Carboplatin in Unresectable Stage III Squamous Cell Lung Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is studying induction nimotuzumab plus gemcitabine and carboplatin followed by surgery to see how well it works in treating patients with unresectable stage III squamous cell lung carcinoma.
Timeline
- Start
- 2015-04-01
- Primary completion
- 2025-10-01
- Completion
- 2027-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 5 unknown | Intravenous |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | Nimotuzumab | Monoclonal antibody | 200 mg | Intravenous |